已收盤 02-06 16:00:00 美东时间
+0.500
+1.40%
今日重点评级关注:RBC Capital:维持Compass Pathways"跑赢大市"评级,目标价从16美元升至21美元;RBC Capital:维持GH Research"跑赢大市"评级,目标价从33美元升至40美元
01-26 14:32
今日重点评级关注:HC Wainwright & Co.:上调Tempest Therapeutics评级至"买入",目标价11美元;Guggenheim:维持Sportradar Gr"买入"评级,目标价从34美元升至35美元
01-23 19:46
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Dime Community Bancshares业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **核心盈利表现:** - 第四季度核心每股收益(Core EPS)为0.79美元,同比增长88% - 第四季度总收入创纪录达到1.24亿美元 - 核心税前拨备前净收入为6150万美元,约占平均资产的163个基点 **资产负债表现:** - 核心存款同比增长12亿美元 - 商业贷款环比增长超过10.75亿美元,同比增长超过5亿美元 - 平均盈利资产环比增长超过6.5亿美元 **资产质量:** - 不良资产(NPAs)降至总资产的34个基点
01-22 12:31
Dime Community shares are trading higher after the company reported better-than...
01-22 00:43
Dime Community Bancshares (NASDAQ:DCOM) reported quarterly earnings of $0.79 per share which beat the analyst consensus estimate of $0.71 by 10.8 percent. This is a 88.1 percent increase over earnings of $0.42 per share
01-21 19:50
Companies Reporting Before The Bell • TE Connectivity (NYSE:TEL) is expected to...
01-21 19:11
Dime Community Bancshares (NASDAQ:DCOM) is set to give its latest quarterly ear...
01-21 00:01
今日重点评级关注:富国银行:维持Milestone Pharmaceuticals"超配"评级,目标价从4美元升至8美元;富国银行:维持Kyverna Therapeutics"超配"评级,目标价从31美元升至33美元
2025-12-17 10:46
Dime Community Bancshares, Inc. (NASDAQ:DCOM) (the "Company" or "Dime"), the parent company of Dime Community Bank (the "Bank"), announced it has received approvals from the Federal Reserve Bank of New York and the New
2025-12-10 05:19
今日重点评级关注:Guggenheim:上调Neumora Therapeutics评级至"买入",目标价14美元;韦德布什:上调Fate Therapeutics评级至"跑赢大市",目标价从5美元升至7美元
2025-10-28 10:08